Certolizumab pegol in severe rheumatoid arthritis. Real-life evidence in an Argentine cohort: goal achievement (t2t) at 3 months and predictive factors.
Introduction: Certolizumab pegol (CTZ) is a tumor necrosis factor-alpha (TNF-α) inhibitor biological agent that has demonstrated efficacy in controlling rheumatoid arthritis (RA). Identifying predictive factors for treatment success and assessing its effectiveness in a real-world clinical setting ar...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Panamerican League of Associations of Rheumatology (PANLAR)
2024-02-01
|
| Series: | Global Rheumatology |
| Subjects: | |
| Online Access: | https://globalrheumpanlar.org/manuscrito-articulo-original/certolizumab-pegol-en-artritis-reumatoidea-severa-evidencia-de-la-vida |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|